Subscribe

SSY Group Limited (2005.HK)

HKD2.45 +0.07 (+2.94%)
HK HKSE Healthcare Medical - Pharmaceuticals
Address Central Plaza 200021
Wan Chai, SH, HK
CEO Ji Guang Qu
Website ssygroup.com.hk
IPO 2005-12-20
ISIN KYG8406X1034

Explore sections of this company profile

Also trades on Hong Kong Stock Exchange · 2005.HK (HKD) Other OTC · LJUIF (USD)
Description

SSY Group Limited, an investment holding company, researches, develops, manufactures, trades in, and sells various pharmaceutical products to hospitals and distributors in the People’s Republic of China and internationally. The company offers intravenous infusion solutions, including non-PVC and upright soft bag, PP plastic bottle, and glass bottle infusion solutions, as well as ampoule injections. It also provides small volume injections, oral preparations, Chinese medicine preparations, and biological preparations, as well as bulk pharmaceutical products and medical materials. In addition, the company is involved in the research, development, and consulting of pharmaceutical technology; provision of logistics services for pharmaceutical products; food, beverages, and catering businesses; and production and sale of methylamine. It sells its products under the Shimen brand name. The company was formerly known as Lijun International Pharmaceutical (Holding) Co., Ltd. and changed its name to SSY Group Limited in May 2015. The company was founded in 1999 and is headquartered in Wan Chai, Hong Kong.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
HKD2.45 +0.07 (+2.94%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
6M
Beta
0.44
Float Shares
988.11M
Free Float %
33.5%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+3.10% -2.10% +1.30% -13.70% -24.10% -17.67% -20.48% -52.35% -54.84% -6.80% +1,899,373.04%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
2.45
DCF (Unlevered) 5.59 +128.3%
DCF (Levered) 0.70 -71.5%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 3 -1
Hold 0 -1
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
3.03
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Medical - Pharmaceuticals: +7.8%
    -27.9% Q4'25: -35.5% (vs Q4'23)
  • ✗
    EPS growth Medical - Pharmaceuticals: +20.2%
    -55.6% Q4'25: -72.1% (vs Q4'23)
  • ✓
    FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%
    +7.5% ★ Q4'25: +24.9% (vs Q4'23)
  • ✗
    EBIT margin Medical - Pharmaceuticals: +6.8%
    +14.3% ★ Q4'25: +11.1% (vs Q4'23)
  • ✗
    ROIC Medical - Pharmaceuticals: +6.1%
    +5.2% Q4'25: +8.2% (vs Q4'23)
  • ✓
    Share dilution Medical - Pharmaceuticals: +0.0%
    -1.0% ★ Q4'25: -1.9% (vs Q4'23)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×
    3.88× Q4'25: 2.29× (vs Q4'23)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.46) × ERP
WACC = 63% × Ke + 37% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 5.63 Current price: 2.45
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2009
actual 		Dec 2010
actual 		Dec 2011
actual 		Dec 2012
actual 		Dec 2013
actual 		Dec 2014
actual 		Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
3 Rev. Ana.
2 EPS Ana. 		Dec 2027
3 Rev. Ana.
2 EPS Ana. 		Dec 2028
2 Rev. Ana.
1 EPS Ana.
Revenue
1.74B
est: 1.78B (-2.2%)
1.97B
est: 2.07B (-4.7%)
2.16B
est: 2.19B (-1.6%)
2.43B
est: 2.55B (-4.8%)
2.75B
est: 2.81B (-2.3%)
2.09B
est: 3.13B (-33.1%)
2.22B
est: 2.19B (+1.7%)
2.36B
est: 2.37B (-0.3%)
3.08B
est: 2.82B (+9.0%)
4.18B
est: 4.14B (+0.9%)
4.64B
est: 4.76B (-2.5%)
4.26B
est: 3.89B (+9.6%)
5.36B
est: 5.56B (-3.7%)
6.43B
est: 6.68B (-3.7%)
6.46B
est: 6.47B (-0.1%)
5.77B
est: 6.45B (-10.4%)
4.17B
est: 4.26B (-2.2%)
4.87B
4.84B – 4.91B
+14.3% YoY
5.51B
5.36B – 5.59B
+13.3% YoY
6.29B
6.29B – 6.29B
+14.1% YoY
EBITDA
377.35M
est: 147.26M (+156.3%)
434.33M
est: 341.20M (+27.3%)
140.63M
est: 408.76M (-65.6%)
522.18M
est: 113.98M (+358.1%)
689.46M
est: 493.07M (+39.8%)
785.38M
est: 655.04M (+19.9%)
750.76M
est: 611.45M (+22.8%)
906.14M
est: 662.59M (+36.8%)
1.11B
est: 930.68M (+19.3%)
1.38B
est: 1.45B (-4.7%)
1.69B
est: 1.56B (+8.6%)
1.09B
est: 1.53B (-28.5%)
1.40B
est: 1.90B (-26.3%)
1.86B
est: 2.16B (-13.9%)
2.11B
est: 1.85B (+14.5%)
1.74B
est: 1.85B (-5.8%)
1.04B
est: 1.22B (-14.8%)
1.39B
1.38B – 1.40B
+14.3% YoY
1.57B
1.53B – 1.60B
+13.3% YoY
1.79B
1.79B – 1.79B
+14.1% YoY
EBIT
282.11M
est: 133.63M (+111.1%)
329.53M
est: 326.77M (+0.8%)
19.88M
est: 344.07M (-94.2%)
369.39M
est: 15.27M (+2,319.4%)
482.54M
est: 409.83M (+17.7%)
617.44M
est: 599.11M (+3.1%)
540.45M
est: 455.79M (+18.6%)
666.60M
est: 570.70M (+16.8%)
853.35M
est: 768.49M (+11.0%)
1.11B
est: 1.24B (-10.8%)
1.42B
est: 1.32B (+7.6%)
776.69M
est: 1.33B (-41.4%)
1.01B
est: 1.65B (-38.6%)
1.49B
est: 1.87B (-20.5%)
1.71B
est: 1.37B (+24.6%)
1.34B
est: 1.37B (-2.0%)
595.52M
est: 902.51M (-34.0%)
1.03B
1.03B – 1.04B
+14.3% YoY
1.17B
1.14B – 1.18B
+13.3% YoY
1.33B
1.33B – 1.33B
+14.1% YoY
Net Income
216.10M
est: 103.05M (+109.7%)
260.59M
est: 251.94M (+3.4%)
-41.40M
est: 275.89M (-115.0%)
281.00M
est: -48.25M (+682.4%)
411.81M
est: 309.41M (+33.1%)
602.93M
est: 457.89M (+31.7%)
403.42M
est: 442.17M (-8.8%)
489.54M
est: 425.14M (+15.1%)
664.72M
est: 586.00M (+13.4%)
911.77M
est: 970.89M (-6.1%)
1.14B
est: 1.08B (+5.4%)
611.97M
est: 1.08B (-43.5%)
785.53M
est: 1.34B (-41.5%)
1.12B
est: 1.19B (-5.8%)
1.32B
est: 1.37B (-3.5%)
1.06B
est: 1.21B (-12.4%)
470.64M
est: 470.64M (+0.0%)
577.09M
576.68M – 577.50M
+22.6% YoY
701.55M
696.87M – 728.22M
+21.6% YoY
897.19M
879.77M – 914.61M
+27.9% YoY
SGA
599.99M
est: 616.58M (-2.7%)
676.70M
est: 698.23M (-3.1%)
908.13M
est: 716.41M (+26.8%)
701.00M
est: 1.06B (-33.8%)
789.24M
est: 771.87M (+2.3%)
484.37M
est: 877.54M (-44.8%)
558.51M
est: 355.22M (+57.2%)
614.91M
est: 588.59M (+4.5%)
962.28M
est: 768.03M (+25.3%)
1.57B
est: 1.38B (+13.1%)
1.64B
est: 1.83B (-10.4%)
1.89B
est: 1.57B (+21.0%)
2.02B
est: 1.94B (+3.8%)
1.95B
est: 2.21B (-12.0%)
1.53B
est: 1.84B (-17.0%)
1.45B
est: 1.84B (-21.3%)
1.07B
est: 1.21B (-11.6%)
1.39B
1.38B – 1.40B
+14.3% YoY
1.57B
1.53B – 1.59B
+13.3% YoY
1.79B
1.79B – 1.79B
+14.1% YoY
EPS
0.09
est: 0.08 (+6.4%)
0.09
est: 0.10 (-8.6%)
-0.01
est: 0.08 (-118.1%)
0.10
est: 0.11 (-14.5%)
0.14
est: 0.14 (-0.5%)
0.17
est: 0.20 (-16.7%)
0.14
est: 0.16 (-11.7%)
0.17
est: 0.18 (-2.9%)
0.23
est: 0.22 (+2.3%)
0.30
est: 0.31 (-2.2%)
0.38
est: 0.36 (+4.6%)
0.20
est: 0.20 (+0.0%)
0.26
est: 0.27 (-1.9%)
0.38
est: 0.38 (+0.2%)
0.44
est: 0.46 (-4.4%)
0.36
est: 0.41 (-13.2%)
0.16
est: 0.17 (-5.9%)
0.20
0.20 – 0.20
+15.7% YoY
0.24
0.24 – 0.25
+23.5% YoY
0.31
0.30 – 0.31
+26.4% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 B+ 3/5 3/5 3/5 4/5 2/5 2/5 4/5
2026-05-28 B+ 3/5 3/5 3/5 4/5 2/5 2/5 4/5
2026-05-27 B+ 3/5 3/5 3/5 4/5 2/5 2/5 4/5
2026-05-26 B+ 3/5 3/5 3/5 4/5 2/5 2/5 4/5
2026-05-22 B+ 3/5 3/5 3/5 4/5 2/5 2/5 4/5
2026-05-21 B+ 3/5 3/5 3/5 4/5 2/5 2/5 4/5
2026-05-20 B+ 3/5 3/5 3/5 4/5 2/5 2/5 4/5
2026-05-19 B+ 3/5 3/5 3/5 4/5 2/5 2/5 4/5
2026-05-18 B+ 3/5 3/5 3/5 4/5 2/5 2/5 4/5
2026-05-15 B+ 3/5 3/5 3/5 4/5 2/5 2/5 4/5
2026-05-14 B+ 3/5 3/5 3/5 4/5 2/5 2/5 4/5
2026-05-13 B+ 3/5 3/5 3/5 4/5 2/5 3/5 4/5
2026-05-12 B+ 3/5 3/5 3/5 4/5 2/5 3/5 4/5
2026-05-11 B+ 3/5 3/5 3/5 4/5 2/5 3/5 4/5
2026-05-08 B+ 3/5 3/5 3/5 4/5 1/5 3/5 4/5
2026-05-07 B+ 3/5 3/5 3/5 4/5 1/5 3/5 4/5
2026-05-06 B+ 3/5 3/5 3/5 4/5 1/5 3/5 4/5
2026-05-05 B+ 3/5 3/5 3/5 4/5 1/5 3/5 4/5
2026-05-04 B+ 3/5 3/5 3/5 4/5 1/5 3/5 4/5
2026-04-30 B+ 3/5 3/5 3/5 4/5 1/5 3/5 4/5
2026-04-29 B+ 3/5 3/5 3/5 4/5 1/5 3/5 4/5
2026-04-28 B+ 3/5 3/5 3/5 4/5 1/5 3/5 4/5
2026-04-27 B+ 3/5 3/5 3/5 4/5 1/5 3/5 4/5
2026-04-24 B+ 3/5 3/5 3/5 4/5 1/5 3/5 4/5
2026-04-23 B+ 3/5 3/5 3/5 5/5 1/5 3/5 4/5
2026-04-22 B+ 3/5 3/5 3/5 5/5 1/5 3/5 4/5
2026-04-21 B+ 3/5 3/5 3/5 5/5 1/5 3/5 4/5
2026-04-20 B+ 3/5 3/5 3/5 5/5 1/5 3/5 4/5
2026-04-17 B+ 3/5 3/5 3/5 5/5 1/5 3/5 4/5
2026-04-16 B+ 3/5 3/5 3/5 5/5 1/5 3/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-1.58B
OE per share TTM
-0.54
Owner's Yield
-23.25%
Maintenance CapEx ratio
506.26%
Maint CapEx / Avg PPE
90.6%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 57 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 iShares MSCI China Small-Cap ETF ECNS 0.21% 134.2K 0.59%
2 Avantis Emerging Markets Small Cap Equity ETF AVEE 0.04% 45.3K 0.42%
3 State Street SPDR S&P Emerging Markets Small Cap ETF EWX 0.04% 257.6K 0.65%
4 iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L 0.03% 23.2K 0.74%
5 iShares MSCI Emerging Markets Small-Cap ETF EEMS 0.02% 92.9K 0.72%
6 iShares MSCI EM Small Cap UCITS ETF IEMS.L 0.02% 76.7K 0.74%
7 State Street SPDR S&P China ETF GXC 0.02% 87.9K 0.59%
8 State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L 0.02% 106.3K 0.55%
9 State Street SPDR S&P Emerging Asia Pacific ETF GMF 0.01% 55.7K 0.49%
10 Avantis Emerging Markets Equity UCITS ETF USD Acc AVEM.L 0.01% 30.1K 0.35%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
108.3K
Shares Outstanding
2.95B

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Jiguang Qu Executive Chairman & Chief Executive Officer 7M male
Xuejun Su Executive Director 2M male
Hing Yeung Chow Chief Financial Officer, Company Secretary & Executive Director 1M male
Guo Meng Deputy GM & Executive Director 1M male
Wanrong Qu Deputy GM & Executive Director 1M female
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Pharmaceuticals